Coronavirus Disease 2019 (COVID-19)
FDA is working with U.S. government partners, including CDC, and international partners to address the pandemic.
Topic Paragraphs
Featured Topics
Recent Press Announcements
Recalls, Market Withdrawals, & Safety Alerts
The FDA provides information gathered from press releases and other public notices about certain recalls of FDA-regulated products. Not all recalls have press releases or are posted on this website
Feb 03
Daiso Issues Alergy Alert for Prepackaged Snacks
Food & Beverages
Feb 03
Fresh Ideation Food Group LLC Recalls Sandwiches and Other Products Because of Possible Health Risk
Food & Beverages
Feb 02
Global Pharma Healthcare Issues Voluntary Nationwide Recall of Artificial Tears Lubricant Eye Drops Due to Possible Contamination
Drugs
Paragraph Header
FDA VOICES: PERSPECTIVES FROM FDA EXPERTS
FDA Approved Many New Drugs in 2022 That Will Improve the Lives of Patients and Consumers
In 2022, CDER approved 37 new drugs never before approved or marketed in the U.S., known as “novel” drugs.
Office of Digital Transformation’s New Focus on Technology Leadership
LMAP lays out our plans to strengthen our technology leadership capabilities to drive change at the business, technology, data, and cybersecurity levels.
FDA’s Cybersecurity Modernization Action Plan
CMAP will leverage Artificial Intelligence and Machine Learning technologies to enhance cyber detection and response capabilities.
Recently Published Guidances
Feb 01
Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products
Drugs
Jan 31
Early Lyme Disease as Manifested by Erythema Migrans: Developing Drugs for Treatment
Drugs
Jan 31
Surveying, Leveling, and Alignment Laser Products
Radiation-Emitting Products